Patents Assigned to Pfizer
  • Patent number: 6248753
    Abstract: This invention relates to compounds of the formula wherein A, B, R3, R4, R5 and R7 are as defined herein, and to their use in the treatment of stress-related diseases.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: June 19, 2001
    Assignee: Pfizer Inc
    Inventor: Yuhpyng L. Chen
  • Patent number: 6248719
    Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The compounds of formula 1 are useful as antibiotic agents. The invention further relates to pharmaceutical compositions and methods of treating bacterial infection using such compounds, and to methods of making the compounds of formula 1.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: June 19, 2001
    Assignee: Pfizer Inc
    Inventor: Yong-Jin Wu
  • Patent number: 6248579
    Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: June 19, 2001
    Assignee: Pfizer Inc
    Inventors: Kim J. Stutzman-Engwall, Hamish McArthur, Yoshihiro Katoh
  • Patent number: 6248717
    Abstract: This invention is directed to the (L)-tartaric acid salt of 2-amino-N-{1-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-[3-oxo-3a-pyridin-2-ylmethyl-2-(2,2,2-trifluoro-ethyl)-2,3,3a,4,6,7-hexahydro-pyrazolo{4,3-c}pyridin-5-yl]-ethyl]-2-methyl-propionamide which is a growth hormone secretagogue and as such is useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compound. The (L)-tartaric acid salt of the compound of this invention is useful in the treatment and/or prevention of osteoporosis, insulin resistance and other conditions or diseases associated with growth hormone deficiency. The (L)-tartaric acid salt of the compound of the present invention is also useful in treating osteoporosis when used in combination with: a bisphosphonate compound; estrogen, Premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: June 19, 2001
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, Paul Andrew Dasilva-Jardine, Bruce Allen Lefker, Jerry Anthony Murry
  • Patent number: 6245321
    Abstract: Oral rinse and dentifrice compositions, comprising a phenolic selected from the group consisting of menthol, eucalyptol, methyl salicylate, thymol, triclosan, and mixtures thereof; and a cyclodextrin selected from the group consisting of hydroxypropyl &bgr;-cyclodextrin, hydroxyethyl &bgr;-cyclodextrin, hydroxypropyl &ggr;-cyclodextrin, hydroxyethyl &ggr;-cyclodextrin, &agr;-cyclodextrin, methyl &bgr;-cyclodextrin, and mixtures thereof. These compositions are useful in retarding the development of plaque, treating gingivitis, and in treating the presence of micro-organisms in the oral cavity.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: June 12, 2001
    Assignee: Pfizer Inc.
    Inventors: Dennis G. A. Nelson, Craig J. Sheehan
  • Patent number: 6245745
    Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X1 and X2 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1, methods of treating bacterial and protozoal infections by administering the compounds of formula 1, and methods of preparing certain compounds of formula 1.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: June 12, 2001
    Assignee: Pfizer Inc
    Inventor: Mathew Merrill Hayward
  • Patent number: 6245765
    Abstract: The invention is directed to the mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one, pharmaceutical compositions containing said ziprasidone mesylate dihydrates, and methods of adminsitering the ziprasidone mesylate dihydrates to treat psychotic diseases.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: June 12, 2001
    Assignee: Pfizer Inc
    Inventors: Frank R. Busch, Carol A. Rose, Russell J. Shine
  • Patent number: 6245766
    Abstract: A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: June 12, 2001
    Assignee: Pfizer Inc
    Inventor: Eric J. Watsky
  • Patent number: 6245787
    Abstract: Methods of treating congestive heart failure in a mammal, especially a human, by co-administration of (1) amlodipine, a pharmaceutically acceptable salt of amlodipine; (2) an ACE inhibitor; and optionally (3) a diuretic and/or (4) digoxin.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: June 12, 2001
    Assignee: Pfizer Inc.
    Inventors: Anne B. Cropp, Allen R. Kraska
  • Patent number: 6242438
    Abstract: The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof. Such compounds and salts are tachykinin antagonists.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: June 5, 2001
    Assignee: Pfizer Inc.
    Inventors: Alexander Roderick MacKenzie, Allan Patrick Marchington, Donald Stuart Middleton, Sandra Dora Meadows
  • Patent number: 6242461
    Abstract: This invention relates to novel aryl substituted azabenzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof wherein n is an integer from 1 to 4 X is CH or N; R1 is H, (C1-C6)alkyl or (C1-C6) alkoxy; R2 is H, (C1-C6)alkyl or (C1-C6) alkoxy; each R3 is independently selected from H, (C1-C6)alkyl (C1-C6) alkyloxy, (C1-C6) alkylthio, halo, nitro, cyano, ethynyl, hydroxy and trifluoromethyl; R4 is H, (C1-C6)alkyl or (C1-C6) alkoxy; R5 is H, (C1-C6)alkyl or (C1-C6) alkyloxy, trifluoromethyl; and W is N or C; Y is N (R4), N, S or O Z is R4, NR4H, O, or OH; Provided that when Y═NR4, W═C, Z═O, there is a single bond between YW and a double bond between WZ; and when Y=O or S, W═C, Z═O, there is a single bond between YW and a double bond between WZ; and when Y═N, W═N, there is a double bond between YW and Z does not exist.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: June 5, 2001
    Assignee: Pfizer Inc.
    Inventors: Steven W. Goldstein, William G. Stirtan, Brian A. Sherer
  • Patent number: 6239147
    Abstract: This invention relates to novel 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives of the formula wherein R1 is C1-C6 alkyl; R2 is hydrogen, C1-C6 alkyl, halo C1-C6 alkyl or phenyl; R3 is hydrogen or halo; and R4 and R5 are independently hydrogen, C1-C6 alkyl or halo C1-C6 alkyl, their pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and the use of such compounds to treat CNS, gastrointestinal and other disorders.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: May 29, 2001
    Assignee: Pfizer INC
    Inventors: R. Scott Obach, Douglas Alan Scully
  • Patent number: 6239285
    Abstract: A process is described for preparing a compound of Formula (1.3.0): comprising: establishing a reaction mixture consisting of in an aprotic solvent; in the presence of NaOH or KOH; optionally in the presence of a phase transfer catalyst, especially a quaternary ammonium salt or a phosphonium salt; followed by heating said reaction mixture under a nitrogen atmosphere.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: May 29, 2001
    Assignee: Pfizer Inc
    Inventors: Timothy Norris, Megan E. Hnatow
  • Patent number: 6239141
    Abstract: This invention relates to suspensions for oral administration comprising novel trovafloxacin zwitterionic crystals, and processes for preparing such crystals. This invention further relates to other pharmaceutical compositions comprising these novel crystals, and to methods of using these suspensions, and these novel crystals in such other dosage forms, for treating bacterial infections in mammals.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: May 29, 2001
    Assignee: Pfizer Inc.
    Inventors: Douglas J. M. Allen, Daniel R. Arenson, S. Sonja Sekulic
  • Patent number: 6235734
    Abstract: This invention involves optionally substituted 1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one derivatives, their preparation, compositions containing same and method of treating addictive disorders and neurological or mental disorders related to a decrease in cholinergic function.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: May 22, 2001
    Assignee: Pfizer Inc
    Inventor: Brian T. O'Neill
  • Patent number: 6235742
    Abstract: Compounds are disclosed which are useful as PDE1 inhibitors.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: May 22, 2001
    Assignee: Pfizer Inc.
    Inventors: Andrew Simon Bell, Nicholas Kenneth Terrett
  • Patent number: 6235267
    Abstract: An oral rinse, dentifrice, or oral gel composition comprising: a) about 0.01 weight % to about 5 weight % of a citrus flavor, citrus flavor ingredient, or mixtures thereof; b) about 0.01 weight % to about 5 weight % of a phenolic, said phenolic selected from the group consisting of menthol, eucalyptol, methyl salicylate, thymol, triclosan, and mixtures thereof; and c) an orally acceptable carrier. The claimed composition is useful in retarding the development of plaque, treating gingivitis, and reducing the viable population of micro-organisms in the oral cavity of a mammal.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: May 22, 2001
    Assignee: Pfizer Inc.
    Inventors: Patricia A. Delli Santi, Dennis G. A. Nelson
  • Patent number: 6235747
    Abstract: The present invention relates to certain 6-phenyl-pyridin-2-ylamine derivatives that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system disorders.
    Type: Grant
    Filed: March 13, 1997
    Date of Patent: May 22, 2001
    Assignee: Pfizer Inc.
    Inventors: John A. Lowe, III, Peter J. Whittle
  • Patent number: 6235750
    Abstract: The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula wherein G, R1 and R2 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system and other disorders.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: May 22, 2001
    Assignee: Pfizer Inc
    Inventor: John A. Lowe, III
  • Patent number: 6235764
    Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: May 22, 2001
    Assignee: Pfizer Inc.
    Inventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant